In our present work the effects of 3 Dau-GnRH-III conjugates – those carrying 4Lys with acetyl or butyryl side chain a “second drug” ([4Lys(Ac)]-GnRH-III(Dau=Aoa), [4Lys(Bu)]-GnRH-III(Dau=Aoa)) and the parent conjugate GnRH-III(Dau=Aoa) (Figure 1) – were investigated in respect of their cell biological activity and their applicability for targeted melanoma therapy. The gene discussed is GNRH1; the disease is melanoma.